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INTRODUCTION 
          Self inflicted violence accounts for almost half of the 1.6 million violent 
deaths that occur every year worldwide. About 63% of global deaths from self 
harm occur in the Asia Pacific region. According to National Crime Records 
Bureau India, every 5 minutes a person commits suicide and 7 attempt to kill 
themselves, forming about 1,00,000 deaths per year.1  Suicide rate was highest 
in the state of Kerala.2 Majority of the victims belonged to the age group 14- 34 
Years3 and Organo Phosphorus Compounds (OPC) were the most common 
agent used for suicide purpose.4     
    With the advance of times, pesticides are now a days widely used for 
modern cultivation methods. Hence, they are readily available as over the 
counter drugs even in village shops and act as common agents for suicidal 
purposes. Currently pesticide self poisoning has become a major clinical 
problem of the developing  countries 5,6  killing around 3,00,000 people each 
year7,8.Most of these deaths occur in rural areas, where easy access to highly 
toxic pesticides turns many impulsive acts of self poisoning into suicide.9 
 In India OPC intake is the commonest method of suicide (40.5%) after 
hanging (49%). Hospital-based data suggest that barbiturates and copper sulfate 
were the commonly used agents for suicide in the years, 1972-1977; however, 
later they were replaced by OP compounds and aluminium phosphide. Organo 
phosphorus insecticides are responsible for as much as 75% of all poisonings in 
our country today.10  
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 The gastrointestinal symptoms following Organophosphorus compound 
poisoning are excessive salivation, nausea, vomiting, abdominal pain and 
diarrhea. Both in experimental studies11,12 and in humans exposed to these 
compounds pancreatic damage has been reported. Pancreatic injury in humans 
may be painless 13 and marked by hyperamylasemia, elevated serum lipase, 
hyperglycemia and glycosuria. Occasionally, symptomatic acute pancreatitis 
can occur.14 The incidence of the latter varies from 7–22% depending on type of 
study and compound.15 The present study was undertaken to find the incidence 
of hyperamylasemia in OPC poisoning and to identify the relation between 
hyperamylasemia and acetylcholinesterase (AChE) levels, which is widely used 
as an indicator of clinical severity 
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REVIEW OF LITERATURE 
ORGANOPHOSPHATES – A BACKGROUND 
History 
 The first potent synthetic organic phosphorus anticholinesterase was 
Tetraethylpyrophosphate (TEPP), which was synthesized by Clermont in 1854. 
16 In 1932, Lange and Krueger wrote of choking and blurred vision following 
inhalation of dimethyl and diethyl phosphorofluoridates. This account inspired 
Schrader in Germany to begin investigating these agents, initially as pesticides, 
and later for use in warfare. During this research, Schrader's group synthesized 
hundreds of compounds, including the popular pesticide Parathion and the 
chemical warfare agents Sarin, Soman, and Tabun. Allied scientists were also 
motivated during the same period by the work, and independently discovered 
other extremely toxic compounds such as Diisopropylphosphofluoridate 
(DFP).17 Since that time, it is estimated that more than 50,000 organic 
phosphorus compounds have been synthesized and screened for pesticidal 
activity, with dozens being produced commercially. 
BASIC STRUCTURE 
        Organophosphorus compounds are basically esters of phosphoric acid or 
of phosphorothioic acids 18. The basic formula is: 
           R1     
R2        P = O or S 
             X (Leaving Group)            
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 The R (R1, R2) denotes either aromatic or aliphatic (ethyl or methyl) 
group. The X is called the leaving group and is the principal metabolite for 
species identification .It determines many of the characteristics of the 
compound and provides a means of classifying OPC’s into 4 main groups.19 The 
Organothiophosphates which contain double bonded sulphur group are 
converted into organophosphates in the liver. 
 Group 1 compounds contain quarternary nitrogen at the X position, and 
are collectively termed Phosphorylcholines. These chemicals originally 
developed as weapons of war20 are powerful cholinesterase inhibitors and can 
also directly stimulate cholinergic receptors, presumably because of their 
structural resemblance to Acetyl choline(Ach).  
 Group 2 compounds are called Fluorophosphates because they possess a 
fluorine molecule as the leaving group. Like group 1 compounds, these 
compounds are volatile and highly toxic, making them well-suited for chemical 
warfare.  
 Group 3 compounds contain a cyanide molecule or a halogen other than 
fluorine. The most well-known agents in this group are Cyanophosphates such 
as Tabun.  
 The fourth group is the broadest and comprises various subgroups based 
on the configuration of the R1 and R2 groups, with the majority falling into the 
category of either a dimethoxy or diethoxy compound. Most of the insecticides 
in use today fall into this last class.20 
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PHARMACOLOGY 
The onset and severity of OP poisoning is determined by the degree, 
route of exposure, the lipid solubility and rate of metabolism of the particular 
compound and activation in liver, required before the compound is active. 
          OP compounds and carbamates are generally highly lipid soluble and 
hence may be systemically absorbed and can cause toxic effects within minutes 
after exposure. They are well absorbed by inhalation, ocular exposure, across 
any mucosal surface, the skin and throughout the gastrointestinal tract (GIT).  
Skin exposure is extremely important, as many cases of toxicity occur after 
cutaneous exposure alone.  Exposure by inhalation results in the fastest 
appearance of toxic symptoms, followed by the gastrointestinal route and finally 
the dermal route.  
 Direct acting OP agents function to inhibit cholinesterase directly, and do 
not require bio-activation in the liver. The insecticide Dichlorvos is an example 
of a direct inhibitor4.  Indirect inhibitors require oxidation by the gastrointestinal 
mucosa and liver to active forms, which then inhibit ChE. Most of the 
commonly encountered insecticides such as Malathion and Parathion are 
indirect agents and require bio-activation before manifesting toxicity. Most of 
the indirect inhibitors undergo desulfuration in the intestinal mucosa and liver 
following absorption to form the more active phosphate metabolites.21  
 The practical importance of this classification is that direct inhibitors 
cause symptoms and signs quickly during or after exposure, whereas in the case 
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of indirect inhibitors symptoms and signs appear later and the effects last longer 
after cessation of exposure.  
Because OP agents are more fat soluble, they may accumulate in the 
body’s fat stores which act as a “reservoir”, prolonging elimination and toxic 
effects.   This has been reported for more lipophilic compounds such as 
Fenthion and Chlorfenthion. 
PATHOPHYSIOLOGY OF OPC POISONING 
The primary  mechanism  of  action  of  OP  pesticides  is  inhibition  of 
acetylcholinesterase  (AChE),  which  is  an  enzyme  found  in  the  nervous 
system. Its normal action is to breakdown acetylcholine (ACh) into acetate and 
choline. Choline is reused. 
Acetylcholine 
 
Cholinesterase 
Choline                             Acetate 
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Figure 1: Action of acetylcholinesterase 
 OPCs inactivate AChE by phosphorylating the serine hydroxyl group 
located at the active site of AChE. The phosphorylation occurs by loss of an OP 
leaving group and establishment of a covalent bond with AChE. Once AChE 
has been inactivated, ACh accumulates throughout the autonomic nervous 
system, the somatic nervous system, and the brain, resulting in overstimulation 
of the muscarinic and nicotinic receptors. 
  
Figure 2: Inactivation of AChE by OPC and accumulation of ACh in the 
synapse. 22 
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 The preganglionic and postganglionic neurons in the parasympathetic 
nervous system release ACh. Postganglionic ACh acts on muscarinic receptors 
on the heart, eyes, glands, GI tract, and respiratory system. Somatic motor 
axons emerge  from  the  spinal  cord  and  directly  innervate  muscle  cells  at  
the neuromuscular junction, releasing ACh on nicotinic receptors.  The brain 
and spinal cord both contain muscarinic and nicotinic receptors.   Cholinergic 
pathways in the brain are associated with various behaviors and functions, 
including hunger, thirst, thermoregulation, respiration, aggression and 
cognition. 
 Once an OPC binds to AChE, the enzyme can undergo 3 processes:  
(1) Endogenous hydrolysis of the phosphorylated enzyme by esterases  , 
(2) Reactivation by a strong nucleophile such as Pralidoxime (2-PAM),  
(3) Biological changes that render the phosphorylated enzyme   inactive 
(ageing). 
 Although the splitting of the choline-enzyme bond in normal ACh 
metabolism is completed within microseconds, the severing of the organic 
phosphorus compound-enzyme bond can be prolonged.23 In organic phosphorus 
compound poisoning, the complex becomes irreversibly bound during the next 
24-72 hours when one of the R groups leaves the phosphate molecule. This step 
is termed ageing.24 De novo synthesis of AChE is required to replenish its 
supply once ageing has occurred. 
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‘Aged’ AChE with its negatively charged phosphate can no longer be 
attacked by a negatively charged nucleophile, i.e.  OH  or  an  oximate  group,  
and  regeneration  is  no  longer  possible. Recovery can take up to 3 months for 
RBC and several weeks for plasma ChE.   
 The time it takes for ageing to occur varies according to the specific 
pesticide, but takes no longer than 48 hrs. Clinically, toxic effects of OP agents 
may persist for more than a week25. Oximes slow down “ageing” of the 
phosphorylated cholinesterase and binds to the OP agent, making it non 
reactive.  This results in ChE regeneration and a rise in serum levels of ChE. 
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Common Organo-phosphate compounds and their brand names 
 
Generic name Brand name 
Acephate 
Chloropyriphos 
Cyclopyrifos 
Diazinon 
Dichlorvos 
Dimethoate 
 
Ethion 
Fenthion 
Formothion 
Malathion 
Methyl Parathion 
Monocrotophos 
Phenthoate 
Phorate 
Phosmet 
Profenfos 
Quinalphos 
 
Trichlorphon 
Acemil,Acet,Agrophate,Acetaf 
Agrofas 20, Chlorofos20,Daspan,Lethal 
Duramet 
Agroziron,Basudin, Bazanon,Tik 20 
Agrovan76,  Agro76, Cockroach killer 
Rogor,Primogor, Krogor, Corothate, 
Agrodimet 30, Tara 909 
Challenge, Demite, Dhanumit 
Agrocidin, Baytex, Lebazate 
Anthio 
Agromal, Bharat, Celthion, Maladol 
Ant repellent, Folidol, Folidol-M,Parahit 
Atom, Azodrin, Microphos, Macrophos 
Agrofen, Delsan, Guard 
Anuphorate, Croton, Dhan,Thimet 
Phosmite 
Carina, Curacrone, Polytrine 
Agroquin, Ekalux,Vikalux,Agroquinol, 
Bayrusil 
Dipterex 
 
TYPES OF CHOLINESTERASE (ChE) 
 Two types of  Cholinesterases19 have been distinguished according to 
their affinities for different substrates, endogenous such as acetylcholine, and 
exogenous such as acetyl-ß-méthylcholine, butyrylcholine and benzoylcholine. 
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Acetylcholinesterase: 
      Present in nervous tissue and erythrocytes, very quickly hydrolyzes 
acetylcholine and acetyl-ß-méthylcholine, but does not hydrolyze 
butyrylcholine. It is called true cholinesterase. 
Butyrylcholinesterase:  
  Present in tissues such as heart and plasma, hydrolyzes acetylcholine, 
benzoylcholine, butyrylcholine but not acetyl-ß-méthylcholine. It is called 
pseudo-cholinesterase. 
Types of Cholinesterase19  
 
Properties Red Blood Cell Cholinesterase 
Butyrylcholinesterase or 
pseudo-cholinesterase 
Advantage Better reflection of 
synaptic inhibition 
Easier to assay, declines faster 
Site RBC (reflects CNS gray 
matter, motor end plate) 
CNS white matter, plasma, 
liver, pancreas, heart 
Regeneration 
(untreated) 
1%/day 25-30% in first 7-10 days 
Normalization 
(untreated) 
35-49 days 28-42 days 
Use Unsuspected prior 
exposure with normal 
plasma cholinesterase 
Acute exposure 
False depression Pernicious anemia, 
hemoglobinopathies, 
antimalarial treatment, 
oxalate blood tubes 
Liver dysfunction, 
malnutrition, hypersensitivity 
reactions, drugs 
(succinylcholine, codeine, 
morphine), pregnancy, genetic 
deficiency 
 
12 
 
 In the acute phase of OP poisoning serum ChE activity is usually 
depressed within a few hours to few days and is also restored to normal levels 
quickly.26 About 3% of the population have a genetic variation manifested by a 
serum cholinesterase deficiency. Pregnancy, acute (or) chronic inflammatory 
conditions, neoplasia, use of certain drugs (succinylcholine, codeine, and 
morphine), malnutrition and liver disease are conditions that also affect serum 
cholinesterase levels, but the depression caused by these conditions is not as 
great as that caused by organophosphate insecticide.   
CLINICAL FEATURES27 
Clinical effects of OPC poisoning are manifested through activation of 
the autonomic and central nervous systems and at nicotinic receptors on skeletal 
muscle.  
Symptoms of acute organophosphate poisoning develop during or after 
exposure, within minutes to hours, depending on the method of exposure. All 
signs and symptoms are cholinergic in nature and affect muscarinic, nicotinic, 
and central nervous system receptors. 
 Signs and symptoms can be divided into three groups: 
 1. Muscarinic effects - Parasympathetic. 
 2. Nicotinic effects - Sympathetic and motor. 
 3. Central nervous system effects - M1 muscarinic receptor stimulation 
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1. Muscarinic Effects 
 Common manifestations include broncho-constriction with wheezing and 
dyspnea, cough, pulmonary edema, vomiting, diarrhoea, abdominal cramps, 
increased salivation, lacrimation, sweating, bradycardia, hypotension, miosis 
and urinary incontinence. 
 Some of these can be remembered by the acronym SLUDGE-Salivation, 
Lacrimation, Urination, Diarrhoea, Gastrointestinal distress and Emesis. 
  Bradycardia and hypotension occur in moderate to severe poisoning. 
2. Nicotinic effects 
 Fasciculations, muscle weakness, and paralysis, hypertension, 
tachycardia, cardiac arrhythmias  and conduction defects.  ECG findings-  sinus 
bradycardia, tachycardia,  inter ventricular conductions delay, idioventricular 
rhythm, multiform premature ventricular extra systoles, ventricular tachycardia 
or fibrillations, torsades de pointes, prolongation of PR interval, ST-T wave 
changes, and atrial fibrillation. 
3. Central Nervous System (CNS) effects 
 Restlessness, headache, tremor, drowsiness, delirium, slurred speech, 
ataxia and convulsions. Coma supervenes in late stages.  
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It is important to note that : 
¾ In any given case there may be tachy- or bradycardia, hypo- or hypertension. 
¾ Miosis being a very characteristic feature may not be present in all cases. In 
fact mydriasis may be present in the initial stages and treatment should not 
be deferred if there is no miosis. Blurred vision may persist for months. 
¾ Ocular absorption may lead to systemic toxicity and miosis may be present 
in spite of systemic treatment and may require topical atropine instillations. 
¾ Exposure to OPC vapors produces immediate symptoms of mucous 
membrane and upper airway irritation and bronchospasm, followed by 
systemic symptoms if patients are exposed to significant concentrations. 
¾ While respiratory failure is the commonest cause of death other causes may 
contribute including hypoxia due to seizures, hyperthermia, renal failure and 
hepatic failure. 
¾ Patients with OPC poisoning and QTc prolongation have more chances of 
developing respiratory paralysis28 than those with normal QTc interval. 
Patients who develop PVCs are more likely to develop respiratory failure 
than patients who do not develop PVCs. 
¾ Aspiration of preparations containing hydrocarbon solvents may cause 
potential fatal lipoidal pneumonitis. 
¾ Parathion is sometimes associated with haemorrhagic pancreatitis which can 
be fatal. Diazinon has also been implicated to cause pancreatic damage. 
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 The critical symptoms in management are the respiratory symptoms.29 
The primary cause of death is respiratory failure. Sufficient muscular 
fasciculations and weakness are often observed as to require respiratory support; 
respiratory arrest can occur suddenly. Likewise, bronchorrhea and 
bronchospasm may often impede efforts at adequate oxygenation of the patient. 
Bronchospasm and bronchorrhea manifest with tightness in the chest, wheezing, 
productive cough, and pulmonary edema. A life threatening severity of 
poisoning is signified by loss of consciousness, incontinence, convulsions, and 
respiratory depression and there usually is a secondary cardiovascular 
component.  
 The classic cardiovascular sign is bradycardia which can progress to sinus 
arrest. However, this may be superseded by tachycardia and hypertension from 
nicotinic (sympathetic ganglia) stimulation.30 Toxic cardiomyopathy has been a 
prominent feature of some severe organophosphate poisoning. 
 Muscle twitching, weakness, tremor, in-coordination, vomiting, 
abdominal cramps, and diarrhoea all signal worsening of the clinical state. 
 In recent works, it has been reported that children, particularly those 
under nine years of age, are unlikely to develop classic “muscarinic” signs of 
OP poisoning.  More often than not, younger children manifest “nicotinic” signs 
of poisoning.  The most common features in pediatric poisoning are CNS 
depression and hypotonia.  
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Intermediate syndrome (IMS)31 
 This syndrome occurs after resolution of the acute cholinergic crisis, 
generally 24-96 hours after exposure. IMS lacks muscarinic symptomatology, 
and appears to result from a combined pre- and post-synaptic dysfunction of 
neuromuscular transmission.   The most common compounds involved in this 
syndrome are Methyl parathion, Fenthion and Dimethoate. 
  Main features are motor cranial nerve palsies, muscle weakness and 
paralysis characterized by weakness of neck flexors and proximal limb muscles 
and acute respiratory paresis. Paralytic signs include inability to sit up or lift the 
neck, ophthalmoparesis, slow eye movements, facial weakness, and difficulty in 
swallowing, limb weakness, areflexia, respiratory paralysis followed by death.  
It is usually due to suboptimal administration of oximes or inadequate 
ventilatory support. Several investigators have suggested development of 
intermediate syndrome due to various causes: 
  1. Inadequate Oxime therapy, 
 2. Dose and route of exposure, 
 3. Chemical structure of Organophosphates,  
 4. Timing of therapy.  
 Management of intermediate syndrome is supportive. Measures as 
oximes and atropine are not found useful. Recent study in India shows one third 
of all poisoning cases admitted in major hospital developed intermediate 
syndrome. 
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Organophosphate-Induced Delayed Polyneuropathy (OPIDP)32   
 A delayed syndrome occurs 1 to 4 weeks after poisoning due to nerve 
demyelination and it is characterized by either flaccid paralysis of distal limbs 
with atrophy or spasticity and ataxia. Relative sparing of the neck muscles, 
cranial nerves, and proximal muscle groups characterize OPIDP. OPIDP is 
motor predominant, and pure sensory neuropathy do not occur .A mixed 
sensory-motor neuropathy usually begins in the legs causing burning sensation 
or tingling and then weakness. This syndrome also does not respond to oximes 
and atropine. Severe cases progresses to respiratory failure and death. The 
delayed neuropathy is most often permanent. The mechanism appears to involve 
phosphorylation of enzyme Neuropathy Target Esterase (NTE) in peripheral 
nervous tissue and results in a “dying-back” pattern of axonal degeneration. 
Recovery can take up to 12 months.  
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Classification of Severity in Organophosphorus Poisoning (NAMBA) 
Type of poisoning Clinical definition 
LATENT 
POISONING 
NAMBA – I 
No clinical manifestations, Diagnosis depends on 
the estimation of serum ChE activity which is 
inhibited by 10-50% 
MILD POISONING, 
NAMBA –II 
The patient can walk but complains of Fatigue, 
headache, dizziness, numbness of extremities, 
nausea and vomiting, excessive sweating and 
salivation, tightness in chest, abdominal cramps or 
diarrhoea; serum ChE activity is 20-50% of normal 
value. 
MODERATEPOISON
ING NAMBA – III 
The patient cannot walk and there is generalized 
weakness, speaking difficulty, muscular 
fasciculations, miosis and severe symptoms 
described above; serum ChE activity is 10 -20% of 
normal value. 
SEVERE 
POISONING 
NAMBA IV 
Unconsciousness, marked miosis and loss of pupil 
reflex to light, muscular fasciculations, flaccid 
paralysis, secretions from the mouth and nose, 
moist rales in the lungs, respiratory difficulty and 
cyanosis; serum ChE activity is lower than 10% of 
normal value. 
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INVESTIGATORY MODALITES:  
1. Cholineesterase levels:  
 Reduction of plasma pseudocholinesterase and/or RBC 
acetylcholinesterase enzyme activities are generally available biochemical 
indicators of excessive organophosphate absorption. Certain organophosphates 
may selectively inhibit either plasma pseudocholinesterase or RBC 
acetylcholinesterase.33 The AChE level can vary widely from person to person. 
A 50% reduction in ChE activity from the baseline may result in acute 
cholinergic symptoms of organophosphate exposure. These values differ among 
laboratories, and the range is very wide, with a 30% spread.    
 Although RBC and plasma (pseudo) cholinesterase levels can both be 
used, RBC cholinesterase correlates better with CNS acetyl cholinesterase 
(AChE) and is, therefore, a more useful marker of organophosphate poisoning.  
• Monitoring serial levels can be used to determine a response to therapy. 
• Cholinesterase levels do not always correlate with severity of clinical 
illness. 
• Falsely depressed levels of erythrocyte cholinesterase can be found in 
pernicious anemia, hemoglobinopathies, use of antimalarial drugs, and 
oxalate blood tubes. 
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2) Serum electrolytes, creatinine and urea: 
 To assess the degree of volume depletion in the presence of muscarinic 
secretory losses from the pulmonary and alimentary tracts. 
3) Blood Urea Nitrogen (BUN) Monitoring: 
 To predict the development of relapse in OP poisoning. Elevation from its 
normal range [8-20 mg/dl] is seen in acute poisoning.34  
4) Arterial Blood Gas (ABG) analysis: 
 To assess the degree of hypoxia and  hypercapnia in the presence of 
respiratory distress from pulmonary congestion.  
5) Serum glucose:  
 Hyperglycemia has been reported in many studies. The increase in serum 
glucose is due to secondary release of catecholamines from the adrenal 
medulla.35 
6) Leukocyte Count:  
 Leucocytosis is a common finding in OP intoxication. It helps to assess 
the prognosis and efficiency of treatment.36 
Imaging Studies 
 Chest X-ray: For evaluating pulmonary edema (or) congestion. 
 CT/USG Abdomen: to evaluate the pancreatic status. 
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Electrocardiogram (ECG) 
 Useful for evaluating the arrhythmias including atrial fibrillation, 
ventricular tachycardia and torsades de pointes (or) QT prolongation.37 
Amylase: 
 Although many tissues synthesize amylase, most of the serum activity 
originates from the pancreas (approximately 40%) and the salivary glands 
(approximately 60%). Electrophoresis shows that serum amylase is of two main 
types: 
 (1) P-type amylase from the pancreas, and  
 (2) S-type amylase from the salivary glands.  
 Fallopian tube secretions, tears, breast milk and sweat have amylases with 
a similar electrophoretic mobility of salivary isoamylase. However, the salivary 
glands account for almost all of the S-type isoamylase. Pancreatic amylase 
enters the blood through an unknown pathway and has a serum half-life of 
about 2 hours. Although the major portion of serum amylase and other 
pancreatic enzymes is probably cleared by the reticulo-endothelial system, 
about one fourth of serum amylase is excreted in its intact form by the kidney.  
Hyperamylasemia is nonspecific because it occurs in many conditions other 
than acute pancreatitis. One half of all patients with a serum amylase elevation 
may not have pancreatic disease.38 In acute pancreatitis, the serum amylase 
concentration is usually more than two to three times the upper limit of normal; 
it is usually less than this with other causes of hyperamylasemia.39 However, 
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this level is not an absolute discriminator. Thus, an increased serum amylase 
level supports rather than confirms the diagnosis of acute pancreatitis. In 
addition, some individuals have persistent hyperamylasemia without clinical 
symptoms. This situation has been reported to be due to macroamylasemia or 
familial pancreatic hyperamylasemia.40 
Metabolic clearance of serum amylase : 
 The exact mechanisms of serum amylase metabolism are still not fully 
understood. Humans who have had a nephrectomy or those who have renal 
insufficiency have average serum amylase levels 50% higher than healthy 
individuals. Therefore, kidneys can be assumed to play a major role in amylase 
metabolism. However, kidney is not the sole organ responsible for amylase 
clearance in humans. The extra renal mechanisms of amylase clearance have not 
been defined. Because of the high serum amylase levels also observed in 
hepatic necrosis and cirrhosis, liver is thought to play a role in amylase 
metabolism. 
CAUSES OF HYPERAMYLASEMIA   
Pancreatic Disease 
1. Acute  or chronic pancreatitis 
2. Pancreatic pseudocyst 
3. Pancreatic trauma (blunt trauma, ERCP related) 
4. Pancreatic carcinoma 
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Non pancreatic Disease 
• Salivary gland lesions  
• Renal insufficiency 
• Tumor (lung, esophagus, ovary, breast) 
• Biliary tract disease (cholecystitis, choledocholithiasis) 
• Perforated peptic ulcer 
• Intestinal obstruction or infarction 
• Postoperative hyperamylasemia 
• Peritonitis 
• Acidosis  
• Ruptured ectopic pregnancy, fallopian or ovarian cysts, and salpingitis 
• Burns 
• Pregnancy 
• Pneumonia, cerebral trauma, burns, abdominal aortic aneurysms ,  
• Anorexia nervosa and bulimia  
• Organophosphate poisoning. 
• Renal transplantation 
• Drugs (morphine, codeine) 
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EFFECT OF ORGANOPHOSPHORUS COMPOUND ON PANCREAS:- 
 Various studies show that there is increased incidence of Pancreatitis and 
its related complications after consumption of organophosphorus compound 
when compared to general population. There is elevated serum Amylase level in 
these patients. 
 Though the exact mechanism for its occurrence is not known , the 
following mechanisms have been suggested . 
a)  OP insecticides increase the intraductal pressure and exocrine pancreatic 
flow. The increase in pressure leads to extravasation of pancreatic fluid. 
This increased pancreatic  exocrine flow could be due to direct 
cholinergic hyper stimulation of pancreatic acinar and ductal cells . 
b)  Experimental data supports the view that these organophosphate 
compounds cause a functional ductal obstruction at the same time as 
stimulation of pancreatic exocrine secretion. 
c)  There is pancreatic interstitial  edema, acinar cell vacuolization, 
hyperamylasemia and hyperlipasemia following ingestion of OP poisoning. 
 
 
 
 
 
 
25 
 
TREATMENT OF OPC POISONING 
            Organophosphate poisoning is a serious condition that needs rapid 
diagnosis and intensive care support. Patients who receive appropriate treatment 
immediately recover from acute toxicity. 
 
PROTECTION: 
 OPC intoxicated patients serve as a source of poisoning for the health-care 
professionals by direct contact. 
 Hence health-care professionals are required to wear PPE (personal 
protective equipments) at least until the patient is externally 
decontaminated.41 
 
DECONTAMINATION: 
 Remove patient from the source of poisoning. 
 All clothing, especially leather should be removed and discarded in a 
ventilated area. 
 Skin and hair decontamination should be done with water irrigation and 
can be enhanced by using alcohol-based soaps. 
 Water irrigation should be used for ocular decontamination. 
 Gastric lavage is indicated in stable patients who have ingested 
contaminated fluids. 
 All the lavaged/aspirated fluids should be safely discarded.  
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The main – stays of treatment are, 
 - Supportive care 
 - Atropine 
 - Oximes 
 - Benzodiazepines 
SUPPORTIVE CARE: 
 * Gastric lavage 
 * Air way control 
 * Oxygenation 
 * Ventilation and 
 * Seizure management. 
STABILIZATION: 
 ABCs: Have a low threshold for early intubation in order to obtain airway 
protection. 
 Avoid mouth-to-mouth resuscitation for the risk of contamination. 
 Start IV fluids as an initial bolus dose of 20ml/kg42. 
ATROPINE: 
 Atropine is an anti-muscarinic agent which competes with ACh for 
receptor binding. 
Targeted End – Points of Atropinisation.41 
 Clear lungs(i.e.) drying of bronchial secretions with normalized oxygen 
saturation 
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 Dry axillae 
 Systolic BP > 80mm Hg. 
 Heart rate > 80 /min 
 No miosis 
 The initial adult dose is 1 to 3 mg IV bolus. Then titrate43 according to 
persistence of bronchorrhea by giving double the previously used dose every 5 
minutes until atropinization achieved. The initial pediatric dose is 0.02mg/kg 
IV. Titrate as in adults. Once the patient is stabilized an infusion of atropine 
should be started with 10% to 20% of the initial atropinization dose per hour 
and should be held once anti-cholinergic effects occur. 
 NOTE: Atropine has no effect on neuromuscular junctions, therefore 
Pralidoxime should be added as early as possible in order to reverse muscle 
weakness. 
Atropine Toxicity:- 
 Excess atropine can cause atropine toxicity characterized by confusion, 
agitation, atropine induced hyperthermia and cardiac arrest. 
Glycopyrrolate  
 It has been studied as an alternative to atropine and found to have similar 
outcomes using continuous infusion. Ampoules of 7.5 mg of glycopyrrolate 
were added to 200 ml of saline and this infusion was titrated to the desired 
effects of dry mucous membranes and heart rate above 60 beats/min. The other 
apparent advantage to this regimen was decreased tendency to develop 
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respiratory infections. This may represent an alternative when there is a concern 
for respiratory infection due to excessive secretions, and in the presence of 
altered level of consciousness where the distinction between atropine toxicity or 
relapse of organophosphate poisoning is unclear.44 
OXIMES: 
Category: Cholinesterase reactivators. 
Oximes are effective in treating nicotinic symptoms by reversing the 
phosphate – ester bond formed between the OP and acetyl cholinesterase and 
this reactivates the enzyme.  It also prevents subsequent binding of insecticides 
to the AChE and accentuates therapeutic effects of atropine. 
 Pralidoxime forms a complex with OPCs that are bound to AChE. The 
Pralidoxime-OP complex is then released from the enzyme and thus 
regenerates AChE function. 
 Once the AChE bound OPCs start ageing, Pralidoxime is rendered 
ineffective. Therefore, early start of Pralidoxime therapy is crucial. 
 Pralidoxime also binds to free OPCs and thus preventing further AChE 
binding. 
 Adult Dosing used to be administered in boluses over given time. New 
evidence, is however recommending infusion regimens. 1-2g of Pralidoxime 
in 100ml NS IV over 20minutes, then infusion at 500mg/hour. 45,46 
 Pralidoxime use longer than 24 hours is indicated if unaged OPCs are 
redistributed from fat tissues. In such cases infusions should be continued 
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until patient remains symptom-free for atleast 12 hours without additional 
atropine doses, or until patient is extubated. 
 Cardiac and respiratory failures have been reported after administration of 
Pralidoxime.47 
 Though Pralidoxime might not be effective in all cases of OPC poisoning 
due to the ageing effect, it is still recommended to be used routinely in order 
to decrease the total atropine requirements. 
BENZODIAZEPINES: 
 Benzodiazepines are the first-line agents for OPC induced seizures.48 
STUDIES ON EFFECT OF OP COMPOUNDS ON SERUM AMYLASE 
LEVELS: 
¾ A prospective study was undertaken in PGIMER,Chandigarh, India between 
July 2001-June 200549 to find the incidence of hyperamylasemia and acute 
pancreatitis in patients with OP poisoning. Of the 79 patients studied, 
patients who presented with cholinergic crisis had >50% reduction in serum 
cholinesterase levels and serum Amylase was found to be elevated (> 200 
S.U) in 37 patients (46.95%). Among them in three patients it was 800 S.U. 
Not all patients showed radiological evidence of acute pancreatitis. Except 
for Fenthion, significant persistent elevation of amylase was not observed. 
Elevated amylase levels were constantly associated with polymorpho 
leucocytosis, hyperglycemia and elevated transaminase levels were noted.  It 
has been concluded that mild elevation of serum Amylase is common in 
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patients with OP poisoning, however acute pancreatitis is rare.      
¾ A retrospective study analysis of medical records of 121 patients with the 
diagnosis of OP poisoning over three years was done in Veterans general 
hospital, National Yang- Ming University in 1998.  Serum amylase,  
pancreatic  amylase,  salivary amylase, lipase and  cholinesterase levels and 
the clinical manifestations were analyzed. It was observed that 44 patients 
(36%) had hyperamylasemia ( Amylase >360 U/L). Lipase was measured in 
28 patients with hyperamylasemia ; nine of 28 had hyperlipasemia (Lipase > 
380 U/L). The finding of hyperamylasemia was closely related to clinical 
severity and presence of shock. Few patients who had elevated lipase levels 
with hyperamylasemia had shown features of acute pancreatitis and thus 
looking for elevated p-lipase may be a better marker than p-amylase to 
diagnose painless acute pancreatitis and elevated p-amyalse levels alone is 
not indicative of acute pancreatitis. 
¾ In an experimental study done at Department of surgery, University of 
Minnesota Medical School, Minneapolis50, the effects of OPC in-vitro on 
pancreatic exocrine function was studied and it was found that the canine 
pancreas pretreated with Iso-OMPA showed a 42-87% greater release of 
amylase in response to acetyl-choline, than was seen in receiving 
acetylcholine alone. 
¾ Study done in Dept. of Anaesthesiology, Afyon Kocatepe University, 
Turkey51 revealed that high dose atropine that is administered for 24 hours or 
the first 4 hours after intoxication prevented severe pancreatitis. This was 
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done only for Fenthion-induced pancreatitis & its influence should be 
studied for other organophosphates in humans. 
¾ A  prospective  study  was  done  by  the  Department  of  Internal  
Medicine,University of Yuzuncu Yil,Medical faculty,Van,Turkey52 in 2002  
to find the  prevalence  of pancreatitis   in OP poisoning. Four of the total 47 
patients with acute OP poisoning had obviously elevated Amylase and 
Lipase levels (Amylase> 300 U/L; Lipase >60 U/L). Only two of the patients 
with Amylase levels between 100 and 300 U/L had elevated levels of Lipase. 
None of the patients with normal Amylase levels had elevated levels of 
Lipase. A total of 12.76% was diagnosed as having acute Pancreatitis. It was 
concluded that acute Pancreatitis is not a rare complication of 
Organophosphorus poisoning.  In order to improve the outcome of OP 
poisoning early diagnosis of acute pancreatitis is important and serum 
Amylase and Lipase levels should be routinely considered carefully.  
¾ A retrospective  study  of  OP  poison  in  intensive  care  unit  was  
performed  to analyze the incidence of respiratory failure by Department of 
Anesthesiology & Critical care medicine, Kyodo general hospital,Ibaraki 
Japan53. Of the 32 op poisoning Patients, 16 developed respiratory failure 
and received ventilatory support. An increase in plasma Amylase above the 
normal range was found in patients who developed respiratory failure. Thus 
in OP poisoning, the elevation of Amylase levels was predictive of 
subsequent respiratory failure. 
32 
 
 
 
AIM OF THE STUDY 
 
1) To estimate serum Amylase and serum cholinesterase levels in acute 
organophosphorus compound poisoning. 
2) To compare its levels with control group.  
3) To compare the serum levels of amylase and cholinesterase in patients 
with OPC poisoning and their association with clinical severity. 
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MATERIALS AND METHODS 
 
Subjects:  
 Patients presenting with Organophosphorus poisoning were the study 
subjects. 
Study design:  
 A cross - sectional study. 
Ethical committee approval:  
 The Ethical committee approval was obtained to carry out the study in the 
hospital. Consent obtained. 
Study setting:   
 Tirunelveli medical college hospital. 
Study duration:  
 Dec 2010– Oct 2011 
Materials: 
A total of 185 patients with organophosphorus compound poisoning 
admitted to the hospital during the study period, out of which 62 were included 
in the study. 
Controls: 
 40 healthy (age matched) individuals were kept as control. 
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Study criteria:  
Inclusion criteria: 
 Patients with a history of exposure to OP poison were the study subjects. 
Exclusion criteria: 
• Patients with indication of exposure to an entirely different poison other 
than OPC  
• Patients with double poisoning 
• Patients who have consumed poison along with alcohol 
• Patients who are chronic alcoholics 
• Patients with history suggestive of gall stone disease 
• History suggestive of parotid gland disease 
• Patients with history of lipid disorders 
• Patients with history of renal or hepatic disease   
• Pregnancy 
• H/o abdominal trauma, Endoscopic Retrograde 
Cholangiopancreatography (ERCP) 
• History of intake of drugs likely to produce pancreatitis-Azathioprine 
• 6-Mercaptopurine, Thiazides, Frusemide, Pentamidine, Steroids, 
valproate Sulphonamides. 
Study protocol: 
Patients admitted in Tirunelveli Medical College & Hospital during the 
study period were included in the study group. A previously designed proforma 
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was used to collect the demographic and clinical details of the patients. 
Collaborating department: 
 Department of Biochemistry, Tirunelveli Medical College, Tirunelveli. 
Exposure assessment: 
The following parameters were analyzed for association with OP 
pesticide exposure. 
• Demography  
          Age  
          Sex 
 Time of Admission 
 Economical Status 
 Familial Status 
 Reason for consumption 
• Poison Particulars 
 Severity grade 
 Symptoms after consumption 
 Immediate steps taken after OP exposure 
• Biochemical evaluation which includes Serum Amylase, serum 
cholinesterase, Blood glucose, urea, creatinine and Liver function tests. 
• Clinical Outcome, Clinical Presentations 
 Pupil size, Pulse rate/min, Blood pressure, Respiratory rate/min,  
Secretions. 
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Sample collection: 
 62 Patients satisfying the inclusion criteria were selected for the study. 
About 3 ml of venous blood were collected in two occasions from each subject 
first sample, at the time of admission (Sample I) and next sample after 24 hours 
(Sample II). The samples were centrifuged at 3000 rpm for 15 minutes.  
 The supernatant serum was separated and freezed. Serum Amylase was 
estimated with the help of kit manufactured by ERBA diagnostics by using 
CNP-G3 method. Normal range: up to 80u/l.  
Serum cholinesterase is measured in our lab by the new DGKC method with the 
use of an auto-analyzer. The normal range provided by our lab is,  
Females: 3930-10800 U/L 
Males    : 4620-11500 U/L 
Limitations of this study: 
a)  In this present study, patients were not subjected to CT / USG Abdomen 
because the study was limited to serum Amylase only. 
b)  Autopsy study of pancreas was not done in the view of social limitation. 
c) Subsets of Amylase such as pancreatic and salivary Amylase was not 
estimated due to laboratory constraints. 
d)  Urinary Amylase was not estimated due to technical limitations. 
e)  Other   biochemical   parameters   related to   pancreatic   involvement   was   
not attempted due to financial constraints. 
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STATISTICAL ANALYSIS: 
 Data analysis was done with the help of computer using Epidemiological 
Information Package (EPI 2002). 
 Using this software, frequencies, percentages, means, standard deviations, 
chi square test, paired ‘t’ test, unpaired ‘t’ test and association were applied. A 
'p' value less than 0.05 is considered significant. 
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TABLE 1: CLINICAL FEATURES 
S. 
No 
Clinical features No of Cases 
Percentage 
(%) 
1. Pinpoint pupil 40 64.5 
2. Depressed mental status 12 19.4 
3. 
Secretions  (45) 
i) Mild 
ii) Moderate  
iii) Severe 
 
23 
20 
2 
 
37.1 
32.2 
3.2 
4. Fasciculation 33 53.2 
5. 
Heart Rate 
             Bradycardia  
 
20 
 
32.3 
6. Hypotension 5 8.1 
7. Convulsions 5 8.1 
8. Respiratory Failure 23 37.1 
 
 Analyzing the occurrence of symptoms in this study, we found that 
secretions(72.5%)  and pin-point pupil(64.5%) are the most common symptoms 
and hypotension(8.1%) and convulsions(8.1%) being the least common 
symptoms occurring in poisoning. 
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TABLE 2: LAB PARAMETERS 
S. 
No 
 
Parameter 
Cases Controls  
‘p’value Mean S.D. Mean S.D. 
1.  Serum amylase–I 
(unit/L) 154.61 121.52 43.95 23.19 
 
< 0.01 
Significant 
2.  Serum 
cholinesterase-I 
(unit/L) 3428.71 1943.56 5449.25 1284.32 
 
< 0.01 
Significant 
3.  Total WBC count 
(cells/cu.mm) 
8503.23 3566.97 7725.00 2601.85 
 
0.237      
4.  Blood sugar  
(mg %) 125.94 36.16 121.03 29.21 
 
0.473 
 
5.  Blood urea              
(mg %) 27.02 7.43 28.83 8.83 
0.268 
 
6.  Serum Creatinine 
(mg %) 0.92 0.21 0.96 0.24 
 
0.459 
 
 
 Compared to control group of our study, the serum amylase and serum 
cholinesterase values of the cases show significance (p<0.05), suggesting 
association between the enzyme levels and the severity. 
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TABLE 3: AMYLASE LEVELS, CHOLINESTERASE LEVELS 
 
S. 
No 
Lab parameter 
Sample I-  
[Taken at the time 
of admission]  
Sample II 
[taken 24 hrs after 
admission] 
  ‘p’ 
Mean  SD Mean SD 
1. Serum Amylase 154.61 121.51 129.27 92.34 <0.001 
2. Serum cholinesterase 3428.71 1943.56 3336.94 1822.54 0.555 
 
 In our study, the serum amylase level at the time of admission is higher 
than its level observed 24 hours after admission. This is statistically significant. 
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TABLE 4: CLINICAL FEATURES AND AMYLASE LEVEL 
 
S. 
No 
Clinical features Serum Amylase I ‘p’ value 
Normal Elevated
1. Pinpoint pupil 14 26 0.067 
2. Depressed mental status 2 10 0.035 
(significant) 
3. Secretions 17 28 0.048 
(significant) 
4. Bradycardia     4 16 0.010 
(significant) 
5. Hypotension   1 4 0.268 
6. Convulsions 1 4 0.268 
7. Fasciculation 10 23 0.025 
(significant) 
8. Respiratory Failure 5 18 0.08 
 
 From observing the above data, we found out that patients with 
symptoms of bradycardia, fasciculations, depressed mental status and secretions 
have significant rise in serum amylase levels. 
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TABLE 5: CLINICAL FEATURES AND SERUM CHOLINESTERASE 
LEVEL 
S.  
No 
Clinical features Serum 
Cholinesterase I 
‘p’ value 
Depressed Normal 
1. Pinpoint pupil 29 
 
11 
 
0.006 
(significant) 
2. Depressed mental status 10 2 
 
0.1 
3. Secretions 
 
31 
 
14 
 
0.051 
4. Bradycardia 
 
17 
 
3 
 
0.005 
(significant) 
5. Hypotension 5 0 
 
0.055 
6. Convulsions 
 
5 0 0.055 
7. Fasciculation 
 
25 8 
 
0.006 
(significant) 
8. Respiratory Failure 
 
19 4 0.005 
(significant) 
 
 By observing the study results, we found that there is significant decrease 
in serum cholinesterase level in patients with respiratory failure, bradycardia 
and fasciculations. 
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TABLE 6: OUTCOME AND AMYLASE LEVELS 
 
S. 
No 
Serum 
Amylase 
Outcome “p”      
value Alive Death 
1.  Normal 22 4 
0.620 2.  Elevated 32 4 
3.  Total 54 8 
 
 Observing the results from our study, we can see that there is no 
significant correlation between the serum amylase level and the outcome.   
 
TABLE 7: OUTCOME AND SERUM CHOLINESTERASE LEVEL 
 
S. 
No 
Serum 
Cholinesterase 
Outcome  
‘p’ Value Alive Death 
1. Normal 24 1  
0.270 2. Depressed 30 7 
3. Total 54 8 
  
 Our study reveals no significant association between the serum 
cholinesterase level and outcome. 
 
 
 
52 
 
DISCUSSION 
 As discussed in the literature, OPC poisoning is a common presentation 
in the Intensive Care Unit (ICU) setup and one with high mortality, much of 
which can be reduced with proper treatment. Defining the factors that affect the 
prediction of mortality and prognosis in OP poisoning will help guide follow-up 
and treatment in the intensive care unit. Serum Amylase and ChE estimation are 
helpful tools in assessment and management of these patients. Here, we perform 
a critical analysis of the observations of our study comparing it with other 
Indian and foreign studies. 
 Age wise distribution  
 By analyzing the data of our study, we found that poisoning is more 
common among the people in the age group of 21-30(40.3%) years followed by 
the people of age group 31-40 years(27.4%).These are consistent with the 
findings of Muhammet Guven et al36  and AM Saadeh et al37, where the mean 
ages were 24.1 and 23.95 respectively. Familial problems are the main reason 
for poisoning in this age group followed by financial problems and other 
reasons like love failure, work related stress. 
Sex wise distribution: 
 In our study, males were more affected (67.7%) than the females 
(32.3%). Similar observations were made by Dalal et al54. Males constituted 
63% of cases of poisoning and still higher incidence was observed by Agarwal 
et al i.e. 72% cases of poisoning in males. 
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Geographic distribution: 
          Our study showed a predominance of rural population consuming OPC. 
This is consistent with Girish Thunga et al55(2008) who reported 66.67%  and 
Dalal et al(1998)70.5%.Obvious reasons being the easy availability of 
pesticides to the rural population.   
Compound: 
 Our study showed that the chemical Dimethoate (27.4%) is the most 
common agent of poisoning followed by  Monochrotophos (19.4%) and 
Quinolphos(14.5%). A similar study in South India by Rao et al56 (2005) 
showed that majority of the cases were admitted due to ingestion of  
Monocrotophos. 
Clinical symptoms 
Both the present study, and the study by Mahdi Balali-Mood et al57, 
found association between the severity of poisoning and clinical manifestations.
 The most marked  muscarinic  signs  in  our  study  population  were,  
miosis  (64.5%) and  excessive secretions (72.5%).The most prominent of the 
nicotinic effect  is  muscular  end  plate  block,  resulting  in  muscle  weakness  
and  fasciculations (53.2%) and respiratory failure(37%).  The CNS symptoms, 
like depressed mental status was found in (19.3%) patients. Similar findings 
have also been reported by Murat Sungur et al35. The results of prospective 
observational study58 done at Dept.of chest medicine, King Edward memorial 
hospital Mumbai supports our observation that clinical features of miosis, 
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unconsciousness and fasciculations are strong predictors of the severity of 
poisoning& ultimately the requirement for ventilator support. 
Biochemical evaluation 
 The biochemical (Blood sugar, Serum creatinine & urea) results have not 
shown much variation from the normal levels in our study. There is no 
statistical significance found for these lab parameters. This was also indicated 
by Mahdi Balali-Mood et al57 .But Singh et al(PGIMER) reported significant 
hyperglycemia with OPC poisoning. Hyperglycemia is attributed to the 
presumptive pancreatic damage associated with OPC poisoning. But there are 
no large prospective studies incorporating imaging of pancreas to address this. 
Respiratory Depression 
The most troublesome complication of OP poisoning was respiratory 
depression which  could  be  due  to  reasons  such  as:  aspiration  of  gastric  
contents,  excessive secretions, pneumonia and septicemia complicating adult 
respiratory distress syndrome. Of the 62 patients, respiratory depression was 
observed in 23 (37.1%) cases. 
 Eddleston et al Srilanka (2006) reported that 24% of patients required 
ventilation. Early recognition of respiratory failure, prompt endotracheal 
intubations and mechanical ventilation are life saving in severe OP poisoning. 
Serum Amylase levels in OP poisoning OP insecticides increase the intraductal 
pressure and exocrine pancreatic flow. The increase in pressure leads to 
extravasation of pancreatic fluid. This increased pancreatic exocrine flow could 
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be due to direct cholinergic hyper stimulation of pancreatic acinar and ductal 
cells. 
 In the study, the Amylase levels were significantly elevated at the time of 
admission [154.61  U/L]  and  have  shown  a  gradual  remission  with  proper  
treatment. 51.6% of our patients were found to have hyperamylasemia. There 
was significant correlation of hyperamylasemia with three of the severe 
manifestations of OPC poisoning, secretions, fasciculations and bradycardia In 
our study, there was no significant correlation between elevated Amylase levels 
and the outcome (mortality). 
 Lee et al59 found 36% of OPC poisoning patients to have hyper 
amylasemia. They also reported significant correlation between elevated 
amylase levels and clinical severity and development of shock. Singh et al 
reported hyperamylasemia incidence of 46.95%.But, there was no significant 
correlation between elevated Amylase levels and the outcome. It is quite 
possible that part of this amylase is salivary, as demonstrated by Lee et al due to 
increased salivation. 
Serum cholinesterase levels in OP poisoning 
 In studies similar to ours, the relationship between acetylcholinesterase 
level and the severity of OP poisoning has been examined, but there has been no 
common conclusion. Goswamy et al56 have stated that measurement of the 
acetylcholinesterase level is useful in predicting the prognosis in OP 
poisoning, but the dominant view is that there is no relationship. In a study 
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conducted by Aygun et al60 on patients with OP poisoning, acetylcholinesterase 
levels on admission were evaluated, and low levels of serum 
acetylcholinesterase were reported to support the diagnosis of acute OP 
poisoning, but acetylcholinesterase levels were not related to clinical 
severity. In the study conducted by Cherian et al on 21 patients with OP 
poisoning, no significant difference was found in serum acetylcholinesterase 
levels between the group treated with Pralidoxime and the group that received 
placebo. Cander et al61 Turkey reported serum acetylcholinesterase level did not 
correlate statistically with mortality and length of stay. Some authors suggest 
that the reduction of serum acetylcholinesterase level and the corresponding 
clinical manifestation should be evaluated together, which would further benefit 
treatment planning.  
 By observing our study, we found that there is significant decrease in 
serum cholinesterase level in patients with miosis, respiratory failure, 
bradycardia and fasciculations (severe OPC poisoning).There is no correlation 
between the cholinesterase levels and the disease outcome from our study. 
 The results of prospective observational study done at Dept. of chest 
medicine, King Edward memorial hospital, Mumbai supports our observation  
that clinical features of miosis, unconsciousness and fasciculations and low 
cholinesterase levels are strong predictors of the severity of poisoning& 
ultimately the requirement for ventilator support. 
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CONCLUSION 
 Though there have been several studies on OPC poisoning reported in 
India and worldwide, consensus is yet to be reached on the roles of serum 
amylase and acetyl cholinesterase in OPC poisoning. Conflicting conclusions 
and widespread variations have been reported by these studies. 
 From our observation, it can be suggested that estimation of serum ChE  
and serum amylase levels would be extremely useful to assess disease severity 
and helps to  identify those  at risk of  developing the  complications  of 
Organophosphorus poisoning.   
 From the observations of our study, the mean Amylase level in first 24 
hours of OP poisoning was 154 U/L which is significantly higher than the 
control groups. 
 The bad  bedside  prognostic  factors  which  correlated  very  well  with  
serum Amylase levels include  secretions, CNS depression, Fasciculations and  
Respiratory failure . 
 Similarly the clinical factors related to severity that correlated with 
acetylcholinesterase include respiratory failure, fasciculations, miosis and 
bradycardia. 
 Though there is no significant correlation between the estimation of 
acetylcholinesterase and amylase with the disease outcome, it is ideal that both 
these investigations be performed and serially monitored in all cases of OPC 
poisoning. Considering that most of our patients present late and are bound to 
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have severe poisoning, it is especially prudent in resource limited setting like 
ours that both these investigations be done. Based on these levels the atropine 
dose could be optimized, since a need for higher dose of atropine in severe 
cases has been evidenced. Thus they may be helpful for the treating physician in 
careful monitoring and aggressive management of severe cases, thus reducing 
mortality and saving crucial lives. 
However, as the study was limited to a small population due to financial 
and laboratory constraints, analysis of a larger group would definitely give an 
insight into the further finer relationship between serum amylase level and 
clinical severity and outcome in OP poisoning. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A study on serum amylase levels in acute organophosphorus poisoning  
PROFORMA 
Name  :     IP No:  
Age / Sex:       D.O.A:  
Residence : urban / rural            D.O.D:  
Occupation: 
Income : 
Time between poisoning & admission:  
Suicidal / accidental / homicidal reason: 
Treatment prior to admission: yes / no 
Poison particulars: 
Name of poison -   
Chemical name:  
Trade name : 
Quantity consumed : 
Nature of poison :  
Liquid / powder / granules  
Mode of consumption : 
Immediate steps taken :  
Symptoms: 
GIT: vomiting /abdominal cramps / abdominal pain / distension / diarrhoea 
CNS: Altered sensorium / Seizures / Blurring of vision / Fasciculations 
(twitching) paralysis (weakness) / Breathlessness 
 
 
Others : Salivation / Frothing  / Sweating / Lacrimation  
Past history: 
Similar attempts before : Yes / No     
Previous psychiatric illness: Yes / No    
Comorbid illness:   
Cardiac disease / Chronic lung disease / Renal failure / Gall stone disease 
neuromuscular disease 
H/o drug intake  
H/o jaundice 
H/o recent surgery  
H/o alcohol intake 
Clinical profile at the time of admission: 
Consciousness  Pulse rate : 
 Pupil size  BP : 
Jaundice  Respiratory rate : 
 
Cyanosis  
Fasciculations  
Convulsions 
RS : Secretions / Respiratory insufficiency 
Abdomen : distension / tenderness / palpable mass / bowel sounds  + / -- 
 
Investigations :  
 
 
TC-            DC-             Hb %-     ESR- 
Blood sugar:          Urea :            Creatinine : 
Liver function tests:  
Serum Bilirubin – total:       Direct:            Indirect: 
SGOT:  SGPT: ALP:    Protein-Total:   Albumin:      Globulin:  
Serum amylase   I:                                     II: 
Serum cholinesterase I:                              II: 
Complications: 
Respiratory failure  Hypotension     Hypokalemia     Pancreatitis 
Arrythmias        Hepatocellular jaundice    
Duration of hospitalization: 
Final outcome:  Full recovery/ Death 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
2-PAM  -  Pralidoxime  
ABG  - Arterial Blood Gas  
Ach  -  Acetyl choline 
AChE  -  Acetylcholinesterase 
BChE  -  Butyrylcholinesterase   
BUN  -  Blood Urea Nitrogen 
ChE  -  Cholinesterase 
CNS  -  Central Nervous System 
ECG  - Electrocardiogram 
GIT  -  Gastrointestinal tract 
IMS  -  Intermediate syndrome 
NTE  -  Neuropathy Target Esterase 
OP  - Organo Phosphorus 
OPC  -  Organo Phosphorus Compounds 
OPIDP  -  Organophosphate-Induced Delayed Polyneuropathy 
PVC  -  Premature Ventricular Contraction 
RBC  -  Red Blood Cell 
TEPP  -  Tetraethylpyrophosphate 
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1 47 M I FA R DIM  + ‐ ++ B N  + ‐ ‐ 230 200 1830 2340 15300 198 32 1.1 A
2 30 F I FA R DIM  + ‐  + N N ‐ ‐ ‐ 108 96 7400 6320 8300 148 28 1 A
3 27 M I FA U PH  +  + +++ B H  +  +  + 452 387 940 1650 21800 85 21 0.8 A
4 15 F I FA R MP ‐ ‐ ‐ N N ‐ ‐ ‐ 92 80 6300 6130 7800 92 18 0.8 A
5 45 M I FI R DIM ‐ ‐ ‐ N N ‐ ‐ ‐ 82 78 5940 6700 6400 113 24 1 A
6 32 F I FA  R MC  +  + ++ B H  + ‐  + 312 278 3300 4500 9700 154 15 0.6 A
7 24 M I FA  U PH ‐ ‐ ‐ N N ‐ ‐ ‐ 134 114 7800 6730 8700 79 24 0.9 A
8 35 M I FA R C ‐ ‐ ‐ N N ‐ ‐ ‐ 64 68 2300 1750 5400 102 30 0.7 A
9 56 M I FI R PH  + ‐ ‐ N N ‐ ‐ ‐ 75 70 5620 4950 6800 125 22 0.7 A
10 25 M I O  U DIM  + ‐  + N N  + ‐ ‐ 48 60 2210 1850 4900 88 19 0.8 A
11 17 F I FA R MP  + ‐ ++ B N  + ‐  + 61 71 5630 1740 5600 138 23 0.9 A
12 29 M I FA U  MC  +  + ++ B H  +  +  + 578 420 660 1370 21300 202 35 1.1 D
13 23 M I O R Q  + ‐ ++ B N ‐ ‐ ‐ 105 85 3200 4820 6700 140 17 0.7 A
14 21 M I FA R MP ‐ ‐ ‐ N N ‐ ‐ ‐ 48 60 5800 6450 7300 98 34 0.8 A
15 33 M I FA U MC  + ‐ ++ N N  + ‐  + 364 268 1350 1960 14500 164 32 0.9 A
16 45 M I FA R Q ‐ ‐ ‐ N N ‐ ‐ ‐ 83 80 4960 5700 9200 138 29 0.8 A
17 23 F I FA U Q ‐ ‐ ‐ N N ‐ ‐ ‐ 43 40 5600 6340 5700 89 28 1 A
18 38 M I FA R DIM ‐ ‐  + B N ‐ ‐ ‐ 68 68 2670 3300 10200 112 18 0.9 D
19 35 F I FA R MC ‐ ‐ ++ N N ‐ ‐ ‐ 48 60 4430 4760 8300 128 28 1.1 A
20 55 M I FA R MC  +  + ++ B N  +  +  + 282 240 1370 1850 10800 158 38 0.9 A
21 21 M I FA U C  + ‐ ‐ N N  + ‐ ‐ 248 210 2650 780 7700 147 29 0.8 A
22 34 M I FI R Q  +  + ‐ B N  + ‐  + 310 268 540 1530 12100 138 18 0.9 A
23 28 M I FA R PH  + ‐ ‐ N N ‐ ‐ ‐ 56 50 670 980 5800 98 26 0.8 D
24 37 F I FA R DIM ‐ ‐ ‐ N N ‐ ‐ ‐ 82 80 4750 5320 4300 132 20 1 A
25 48 M I FI R Q  +  + ++ B N  + ‐ ‐ 278 210 2450 1800 9800 172 32 1.2 A
    CLINICAL FEATURES
26 18 F I O R DIM  + ‐ ++ N N ‐ ‐ ‐ 164 110 1240 1830 6800 88 34 0.9 A
27 45 M I FA R DIM  + ‐  + N N  + ‐ ‐ 72 60 4760 3350 5700 72 26 0.8 A
28 28 F I FA U MC  + ‐  + B N  + ‐  + 180 168 5630 1750 12300 162 34 1.2 D
29 24 M I FA R MP  +  + +++ B H  +  +  + 210 198 2200 3970 10200 148 26 0.8 A
30 36 M I FI R MP  + ‐  + N N ‐ ‐ ‐ 52 60 1730 3340 6300 96 29 0.9 A
31 20 M I FA R PH ‐  + ++ N N ‐ ‐ ‐ 221 200 6340 4780 9900 88 24 0.8 A
32 34 M I FI R MC ‐ ‐ ‐ N N ‐ ‐ ‐ 37 60 2300 2850 5500 79 27 0.7 A
33 26 M I FA U MC  + ‐  + B N ‐ ‐  + 158 110 1640 2760 10200 138 20 0.9 A
34 38 M I FA R DIM  + ‐ ++ N N  + ‐  + 179 120 3450 2370 8800 127 27 0.8 A
35 21 F I FA R C ‐ ‐ ‐ N N ‐ ‐ ‐ 38 50 4570 5600 5600 134 45 0.9 A
36 29 F I FI R DIM ‐ ‐ + N N  + ‐ ‐ 214 186 1720 2450 7300 96 48 1.4 A
37 17 M I FA U P   + ‐  + B N  + ‐  + 48 40 3560 2980 4900 112 36 1 A
38 28 F I FA R PH  + ‐ ++ B N  + ‐ ‐ 256 210 4780 1750 11200 168 47 1.5 A
39 33 M E  ‐‐ R C  + ‐  + N N  + ‐  + 29 30 6750 5870 7700 82 17 0.1 A
40 38 M I FA R Q  + ‐ ++ N N  + ‐  + 318 260 680 1340 10800 172 32 0.9 D
41 45 M I FA R DIM ‐ ‐ ‐ N N ‐ ‐ ‐ 32 40 780 1650 3800 132 28 0.8 A
42 21 F I FA U DIM  + ‐  + N N  + ‐ ‐ 168 110 3980 2780 6700 112 19 0.7 A
43 17 F I FA R MC ‐ ‐  + N N ‐ ‐ ‐ 47 40 5830 5400 4600 98 18 0.7 A
44 28 M I FI R MC  + ‐ ‐ N N  + ‐ ‐ 62 60 4750 3900 5200 89 23 0.9 A
45 31 M I FA R P ‐ ‐ ‐ N N ‐ ‐ ‐ 75 70 4960 6300 6300 78 21 1.2 A
46 24 F I FA U MP ‐ ‐  + N N ‐ ‐ ‐ 58 54 5700 5340 5800 138 19 1.1 A
47 29 M I FI U DIM  +  + ++ B N  + ‐  + 176 110 3780 2750 9900 127 31 1.2 A
48 36 M I O R CH  + ‐ ++ B H  +  +  + 268 220 1840 940 12100 189 36 1.2 D
49 16 M I FA R DIM  + ‐ + B N ‐ ‐  + 247 200 1370 990 10700 132 30 1.1 A
50 23 M I FA R DIM  +  +  + N N ‐ ‐  + 59 60 4780 5300 7800 113 28 0.9 D
51 29 F I FA R PH  + ‐  + B N  + ‐  + 340 290 2730 1100 11800 178 30 1.1 A
52 56 M I FI R MC ‐ ‐ ++ N N  + ‐ ‐ 38 40 1840 2700 5700 99 28 0.9 A
53 37 F I FI R MP  + ‐  + N N  + ‐ ‐ 57 40 1640 3670 4400 89 27 1.1 D
54 29 M I FA U PH  + ‐  + N N ‐ ‐ ‐ 72 87 3300 3560 6500 84 19 0.8 A
55 32 M I FA R DIM  +  +  + B N  + ‐  + 430 290 750 1100 13200 221 31 1.2 A
56 21 F I FA R Q  +  + ++ N N  + ‐  + 196 119 2560 1340 9700 148 36 1.2 A
57 64 F I FI U CH  + ‐  + N N  + ‐  + 168 140 2300 1780 8300 137 32 1.1 A
58 18 M I O R P ‐ ‐  + N N  + ‐  + 278 240 1680 2350 10700 162 29 1 A
59 43 M I FA R MC ‐ ‐  + N N ‐ ‐ ‐ 48 50 4980 5320 6300 192 18 0.8 A
60 38 M I FA R Q  + ‐  + N N ‐ ‐ ‐ 118 89 3640 3430 5600 88 19 0.9 A
61 29 F I FI U DIM ‐ ‐  + N N  + ‐ ‐ 164 110 2370 1830 7700 108 23 0.8 A
62 58 M I FI R Q  + ‐  + N N  + ‐ ‐ 58 53 5300 4750 6800 94 18 0.8 A
63 22 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   53 25 4750 4900 9200 113 31 0.8 A
64 43 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   14 65 5300 4930 5700 126 36 0.9 A
65 19 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   15 89 7840 7650 10200 79 30 0.8 A
66 45 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   43 44 7900 7690 8300 102 28 1 A
67 25 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   21 52 6300 5900 10800 125 30 0.9 A
68 34 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   37 27 3780 4800 7700 88 28 1.1 A
69 26 F      ‐        ‐   U      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   89 42 4300 4700 12100 138 27 0.9 A
70 19 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   78 5750 5300 5800 202 19 0.8 A
71 49 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   53 34 4750 3600 4300 140 31 0.9 A
72 44 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   88 47 4900 5300 5500 98 36 0.8 A
73 27 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   11 28 6700 7120 10200 164 32 1 A
74 23 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   19 30 5300 4930 8800 138 29 1.2 A
75 17 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   25 14 6300 5740 5600 89 18 0.9 A
76 58 M      ‐        ‐   U      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   56 15 5740 6320 7300 112 19 0.8 A
77 22 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   32 43 7300 4980 4900 128 27 1.2 A
78 25 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   41 21 6750 4760 11200 158 20 0.8 A
79 54 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   25 37 4200 3870 7700 147 27 0.9 A
80 24 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   42 89 4860 4430 10800 132 45 1.4 A
81 56 F      ‐        ‐   U      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   53 78 6750 6300 3800 112 48 1 A
82 42 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   14 53 5800 5340 6700 98 36 1.5 A
83 32 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   15 24 5750 6340 4600 89 47 0.1 A
84 42 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   43 39 5400 5740 5200 78 33 0.9 A
85 28 F      ‐        ‐   U      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   21 30 4750 4400 6300 138 32 0.8 A
86 29 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   37 33 5460 4700 5800 127 52 0.7 A
87 16 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   89 93 3800 4350 10700 189 18 0.7 A
88 33 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   78 80 1980 3670 7800 132 32 0.9 A
89 37 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   53 40 7560 5400 11800 113 28 1.2 A
90 21 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   78 69 5300 5640 5700 111 21 1.1 A
91 64 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   25 25 7800 6700 4400 89 18 1.2 A
92 33 M      ‐        ‐   U      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   65 33 5360 4980 6500 84 24 1.2 A
93 45 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   89 79 4750 5300 13200 129 15 1.1 A
94 18 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   44 43 5340 4780 9700 148 24 0.9 A
95 22 M      ‐        ‐   U      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   52 21 4670 3900 8300 137 30 1.1 A
96 28 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   27 37 5100 5800 7300 162 22 0.9 A
97 31 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   42 31 4930 5640 4900 112 19 1.1 A
98 37 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   52 44 3480 4450 11200 88 23 0.8 A
99 40 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   34 53 6700 5780 7700 108 35 1.2 A
100 24 M      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   47 32 5800 3780 10800 89 17 1.2 A
101 20 F      ‐        ‐   R      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   28 40 3900 5640 3800 130 34 0.7 A
102 33 M      ‐        ‐   U      ‐       ‐       ‐       ‐   N N     ‐       ‐       ‐   30 27 4870 4300 6700 99 32 0.9 A
 
Key to master Chart
I ‐ Ingestion
Fa ‐ Family Problems
Fi ‐ Financial Problems
O ‐ Others (Chronic illness, love failure, etc.,)
W ‐ Water
A ‐ Alive
D ‐ Death
R ‐ Rural
U ‐ Urban
N ‐ Normal
B ‐ Bradycardia
H ‐ Hypotension
Q ‐ Quinolphos
PH ‐ Phorate
P ‐ Parathion
MP ‐ Methyl Parathion
MC ‐ Monochrotophos
DiM ‐ Dimethoate
CH ‐ Chlorpyrifos
C ‐ Cyclopyrifos
